The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Open accessAbstract
INTRODUCTION: To evaluate the efficacy of empagliflozin compared to pioglitazone in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM). METHODS: In this prospective randomized, double-blind, placebo-controlled trial, we assigned 106 patients with NAFLD and T2DM to receive empagliflozin 10 mg (n = 35), pioglitazone 30 mg (n = 34), or placebo (n = 37) for 24 weeks. Liver fat content and liver stiffness were measured using fibroscans. Body composition assessment was performed by dual-energy x-ray absorptiometry (DEXA) scans. The primary end point was change from baseline in liver steatosis, using the controlled attenuation parameter (CAP) score. RESULTS: A borderline significant decrease in CAP score was observed with empagliflozin compared to placebo, mean difference: - 29.6 dB/m (- 39.5 to - 19.6) versus - 16.4 dB/m (- 25.0 to - 7.8), respectively; p = 0.05. Using multivariate analysis, we observed a significant reduction in the placebo-corrected change in liver stiffness measurement (LSM) with empagliflozin compared to pioglitazone: - 0.77 kPa (- 1.45, - 0.09), p = 0.02, versus 0.01 kPa (95% CI - 0.70, 0.71, p = 0.98), p for comparison = 0.03. Changes in serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT), fasting insulin, homeostatic model assessment for insulin resistance (HOMA-IR), HOMA2-IR, fibrosis-4 index (FIB4 index), NAFLD fibrosis score, aspartate aminotransferase to platelet ratio index (APRI), android/gynecoid ratio (A/G ratio), and skeletal muscle index (SMI) were comparable between the two treatment groups, while significant reductions of the body weight and visceral fat area were observed only in the empagliflozin group (p < 0.001 and p = 0.01, respectively) and both were increased in the placebo and pioglitazone groups. There were no serious adverse events in either group. CONCLUSION: Treatment for 24 weeks with empagliflozin, in contrast to pioglitazone, was associated with improvement of liver steatosis and fibrosis in patients with NAFLD and T2DM. In addition, body weight and abdominal fat area were decreased in the empagliflozin group. TRIAL REGISTRATION: Iranian Registry of Clinical Trials (IRCT), IRCT20190122042450N3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Empagliflozin (EMPA), a highly selective inhibitor of sodium-glucose co-transporter 2 (SGLT2), exhibits potential therapeutic benefits for liver steatosis; however, the underlying mechanism remains incompletely elucidated.”
From SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · cited 1×
“Furthermore, the FIB-4 (fibrosis 4) index [39] was calculated using the following formula: FIB-4 index = [age 9 AST (units/l)]/(platelet count (9 10(9)/l) 9 [ALT (units/l)].”
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,255
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Farrell, G. C., & Larter, C. Z. (2006) · Hepatology · doi:10.1002/hep.20973 · Cited by 2,428
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,429
Eddowes, P. J., Sasso, M., Allison, M., Tsochatzis, E. A., Anstee, Q. M., Sheridan, D. A., Guha, I. N., Cobbold, J., Deeks, J. J., Paradis, V., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.042 · Cited by 1,425
Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study
Foucher, J. (2005) · Gut · doi:10.1136/gut.2005.069153 · Cited by 1,307
Taylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Adams, L. A., Sanderson, S. O., Lindor, K. D., & Angulo, P. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.012 · Cited by 912
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 873
Sasso, M., Beaugrand, M., de Lédinghen, V., Douvin, C., Marcellin, P., Poupon, R. Y., Sandrin, L., & Miette, V. (2010) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2010.07.005 · Cited by 864
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., et al. (2004) · Hepatology · doi:10.1002/hep.20012 · Cited by 726
Magnetic Resonance Elastography for the Noninvasive Staging of Liver Fibrosis
Huwart, L., Sempoux, C. L., Vicaut, É., Salameh, N., Annet, L., Danse, É., Peeters, F., ter Beek, L. C., Rahier, J., Sinkus, R., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.076 · Cited by 726
Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., Bansal, B., Kaur, P., Jevalikar, G., Gill, H. K., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0165 · Cited by 662
Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study
Poonawala, A., Nair, S. P., & Thuluvath, P. J. (2000) · Hepatology · doi:10.1053/jhep.2000.17894 · Cited by 566
Xu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Mayoux, E., Kaneko, S., & Ota, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.028 · Cited by 512
Mantovani, A., Petracca, G., Beatrice, G., Tilg, H., Byrne, C. D., & Targher, G. (2021) · Gut · doi:10.1136/gutjnl-2020-322572 · Cited by 481
Wu, J. H. Y., Foote, C., Blomster, J., Toyama, T., Perkovic, V., Sundström, J., & Neal, B. C. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00052-8 · Cited by 479
Nobili, V., Vizzutti, F., Arena, U., Abraldeṣ, J. G., Marra, F., Pietrobattista, A., Fruhwirth, R., Marcellini, M., & Pinzani, M. (2008) · Hepatology · doi:10.1002/hep.22376 · Cited by 433
Degos, F., Perez, P., Roche, B., Mahmoudi, A., Asselineau, J., Voitot, H., & Bédossa, P. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.035 · Cited by 429
Hawley, S. A., Ford, R. J., Smith, B. K., Gowans, G. J., Mancini, S. J., Pitt, R. D., Day, E. A., Salt, I. P., Steinberg, G. R., & Hardie, D. G. (2016) · Diabetes · doi:10.2337/db16-0058 · Cited by 401
Shimizu, M., Suzuki, K., Kato, K., Jojima, T., Iijima, T., Murohisa, T., Iijima, M., Takekawa, H., Usui, I., Hiraishi, H., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13520 · Cited by 393
Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.05.014 · Cited by 315
Salgado, A. L. F. D. A., Carvalho, L. D., Oliveira, A. C., Santos, V. N. D., Vieira, J. G., & Parise, E. R. (2010) · Arquivos de Gastroenterologia · doi:10.1590/s0004-28032010000200009 · Cited by 315
Ito, D., Shimizu, S., Inoue, K., Saito, D., Yanagisawa, M., Inukai, K., Akiyama, Y., Morimoto, Y., Noda, M., & Shimada, A. (2017) · Diabetes Care · doi:10.2337/dc17-0518 · Cited by 290
Le, M. H., Devaki, P., Ha, N. B., Jun, D. W., Te, H. S., Cheung, R. C., & Nguyen, M. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173499 · Cited by 287
The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease
Pοlyzos, S. A., Kountouras, J., Zavos, C., & Tsiaousi, E. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01176.x · Cited by 282
Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
Dai, W., Ye, L., Liu, A., Wen, S. W., Deng, J., Wu, X. Y., & Lai, Z. (2017) · Medicine · doi:10.1097/md.0000000000008179 · Cited by 268
Hirose, H., Kawai, T., Yamamoto, Y., Taniyama, M., Tomita, M., Matsubara, K., Okazaki, Y., Ishii, T., Oguma, Y., Takei, I., et al. (2002) · Metabolism · doi:10.1053/meta.2002.30506 · Cited by 235
Komiya, C., Tsuchiya, K., Shiba, K., Miyachi, Y., Furuke, S., Shimazu, N., Yamaguchi, S., Kanno, K., & Ogawa, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151511 · Cited by 232
Zarski, J., Stürm, N., Guechot, J., Paris, A., Zafrani, E., Asselah, T., Boisson, R. C., Bosson, J., Guyader, D., Renversez, J., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.05.024 · Cited by 211
Liver and diabetes. A vicious circle
Loria, P., Lonardo, A., & Anania, F. A. (2012) · Hepatology Research · doi:10.1111/j.1872-034x.2012.01031.x · Cited by 208
Taheri, H., Malek, M., Ismail‐Beigi, F., Zamani, F., Sohrabi, M., Babaei, M. R., & Khamseh, M. E. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01498-5 · Cited by 197
Self-citationShibuya, T., Fushimi, N., Kawai, M., Yoshida, Y., Hachiya, H., Ito, S., Kawai, H., Ohashi, N., & Mori, A. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13061 · Cited by 196
Lai, L.-L., Vethakkan, S. R., Nik Mustapha, N. R., Mahadeva, S., & Chan, W.-K. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-5477-1 · Cited by 191
Pathophysiology of Non Alcoholic Fatty Liver Disease
Petta, S., Gastaldelli, A., Rebelos, E., Bugianesi, E., Messa, P., Miele, L., Svegliati‐Baroni, G., Valenti, L. V. C., & Bonino, F. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122082 · Cited by 182
British Journal of Medicine and Medical Research
Lanza, A., Scognamiglio, F., Femiano, F., & Lanza, M. (2017) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr · Cited by 178
Neeland, I. J., McGuire, D. K., Chilton, R., Crowe, S., Lund, S. S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115616901 · Cited by 168
Ohki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., Tagawa, K., Omata, M., & Koike, K. (2012) · The Scientific World Journal · doi:10.1100/2012/496453 · Cited by 139
Sasaki, T., Sugawara, M., & Fukuda, M. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12851 · Cited by 121
Genetic factors that affect nonalcoholic fatty liver disease: A systematic clinical review
Severson, T. J., Besur, S. V., & Bonkovsky, H. L. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i29.6742 · Cited by 107
Lee, Y., Kim, J. H., Kim, S. R., Jin, H. Y., Rhee, E., Cho, Y. M., & Lee, B. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2017.32.1.60 · Cited by 106
NAFLD—the next global epidemic
Ray, K. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.197 · Cited by 96
Fujii, H., Imajo, K., Yoneda, M., Nakahara, T., Hyogo, H., Takahashi, H., Hara, T., Tanaka, S., Sumida, Y., Eguchi, Y., et al. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14595 · Cited by 94
Roulot, D. M., Roudot‐Thoraval, F., Nkontchou, G., Kouacou, N., Costes, J., Elourimi, G., Clésiau, H. L., Ziol, M., & Beaugrand, M. (2017) · Liver International · doi:10.1111/liv.13481 · Cited by 94
Phielix, E., Szendroedi, J., & Roden, M. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.06.006 · Cited by 92
Therapy of nonalcoholic fatty liver disease: current status.
Duvnjak, M., Tomašić, V., Gomerčić, M., Duvnjak, L. S., Baršić, N., & Lerotić, I. (2009) · PubMed · Cited by 82
Ohki, T., Isogawa, A., Toda, N., & Tagawa, K. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0383-1 · Cited by 80
Takase, T., Nakamura, A., Miyoshi, H., Yamamoto, K., & Atsumi, T. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0295 · Cited by 76
Blonde, L., Stenlöf, K., Fung, A., Xie, J., Canovatchel, W. J., & Meininger, G. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1169894 · Cited by 74
Seko, Y., Sumida, Y., Sasaki, K., Itoh, Y., Iijima, H., Hashimoto, T., Ishii, S., & Inagaki, N. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1364-8 · Cited by 70
Grgurević, I., Podrug, K., Mikolašević, I., Kukla, M., Madir, A., & Tsochatzis, E. A. (2020) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2020/9181368 · Cited by 68
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66 · cited 1×
“However, despite the role of incretin hormones in NAFLD pathogenesis [17] and various interventions targeting the gut-pancreas-liver axis, in NASH treatment no approved treatment is currently available [17, 18].”
BackgroundKurinami, N., Sugiyama, S., Yoshida, A., Hieshima, K., MIYAMOTO, F., Kajiwara, K., Jinnouch, K., Jinnouchi, T., & Jinnouchi, H. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.017 · Cited by 62
Thiazolidinediones and the liver in humans
Yki‐Järvinen, H. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283321d37 · Cited by 60
Ballestri, S., Capitelli, M., Fontana, M. C., Arioli, D., Romagnoli, E., Graziosi, C., Lonardo, A., Marietta, M., Dentali, F., & Cioni, G. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01307-z · Cited by 59
You, S. C. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i4.1158 · Cited by 57
Ohta, A., Kato, H., Ishii, S., Sasaki, Y., Nakamura, Y., Nakagawa, T., Nagai, Y., & Tanaka, Y. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1363888 · Cited by 57
Banini, B. A., & Sanyal, A. J. (2016) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s18885 · Cited by 52
Doycheva, I., Patel, N. S., Peterson, M. R., & Loomba, R. S. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.10.008 · Cited by 52
Non-alcoholic fatty liver disease: a diabetologist’s perspective
Pappachan, J. M., Antonio, F. A., Edavalath, M., & Mukherjee, A. (2013) · Endocrine · doi:10.1007/s12020-013-0087-8 · Cited by 50
Seino, Y., Yabe, D., Sasaki, T., Fukatsu, A., Imazeki, H., Ochiai, H., & Sakai, S. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12694 · Cited by 50
Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
Miyake, T., Yoshida, S., Furukawa, S., Sakai, T., Tada, F., Senba, H., Yamamoto, S., Koizumi, Y., Yoshida, O., Hirooka, M., et al. (2018) · Open Medicine · doi:10.1515/med-2018-0059 · Cited by 49
Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus.
Ribola, F. A., Cançado, F. B., Schoueri, J. H. M., Toni, V. F. D., Medeiros, V. H. R., & Feder, D. (2017) · PubMed · Cited by 44
Shao, S.-C., Kuo, L.-T., Chien, R.-N., Hung, M.-J., & Lai, E. C.-C. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001956 · Cited by 43
Revista de Gastroenterología de México 2008
Editores, L. (2008) · Revista Portuguesa de Pneumologia · Cited by 43
Hsing, J. C., Nguyen, M. H., Yang, B., Yan, M., Han, S. S., Pung, E., Winter, S. J., Zhao, X., Gan, D., Hsing, A. W., et al. (2019) · Hepatology Communications · doi:10.1002/hep4.1392 · Cited by 39
Tanaka, K., Takahashi, H., Hyogo, H., Ono, M., Oza, N., Kitajima, Y., Kawanaka, M., Chayama, K., Saibara, T., Anzai, K., et al. (2018) · Hepatology Research · doi:10.1111/hepr.13282 · Cited by 37
Bouchi, R., Nakano, Y., Ohara, N., Takeuchi, T., Murakami, M., Asakawa, M., Sasahara, Y., Numasawa, M., Minami, I., Izumiyama, H., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0384-7 · Cited by 33
Arase, Y., Shiraishi, K., Anzai, K., Sato, H., Teramura, E., Tsuruya, K., Hirose, S., Deguchi, R., Toyoda, M., Mine, T., et al. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00785-6 · Cited by 32
Ting, Y., Wong, S., Zaini, A. A., Mohamed, R. B., & Jalaludin, M. Y. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00491 · Cited by 27
Velasco, J. A. V.-R., García-Jiménez, E. S., García‐Zermeño, K. R., Morel-Cerda, E. C., Aldana-Ledesma, J. M., Castro‐Narro, G., Cerpa‐Cruz, S., Tapia-Calderón, D. K., Mercado-Jauregui, L. A., & Contreras-Omaña, R. (2019) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2019.05.004 · Cited by 21
Kusunoki, M., Natsume, Y., Sato, D., Tsutsui, H., Miyata, T., Tsutsumi, K., Suga, T., & Oshida, Y. (2016) · Drug Research · doi:10.1055/s-0042-111515 · Cited by 19
Kusunoki, M., Natsume, Y., Miyata, T., Tsutsumi, K., & Oshida, Y. (2018) · Drug Research · doi:10.1055/a-0585-0145 · Cited by 17
Yen, Y., Chen, J., Cheng, B., Chen, J., Chang, K., Tseng, P., Wu, C., Tsai, M., Lin, M., & Hu, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176027 · Cited by 17
Katsuyama, H., Hakoshima, M., Iijima, T., Adachi, H., & Yanai, H. (2020) · Journal of Endocrinology and Metabolism · doi:10.14740/jem632 · Cited by 9
Khan, R. S., & Newsome, P. N. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05573-y · Cited by 6
Degos, F., Perez, P., Asselineau, J., & Bédossa, P. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.01.015 · Cited by 5
Increased Hemoglobin A1c Correlates with Increased Liver Stiffness in a Mexican-American Population
Watt, G. P., Lee, M., Pan, J., Fallon, M. B., McCormick, J. B., & Fisher‐Hoch, S. P. (2018) · Diabetes · doi:10.2337/db18-2391-pub · Cited by 2
Bileaflet valve replacement: complications and costs.
Migliaccio–Walle, K., Klittich, W. S., Banks, J., O'Brien, J. A., & Jaime, J. (1996) · PubMed · Cited by 2
Mathur, P., Mathur, S., Punjabi, P., Vaishnav, R., & Mathur, M. (2016) · Journal of Advances in Medicine and Medical Research · doi:10.9734/bjmmr/2016/21556 · Cited by 1
Cited by
Sorted by citations
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 387
Negi, C. K., Babica, P., Bajard, L., Vašků, J. B., & Tarantino, G. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 196
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Ανδρουτσάκος, Θ., Ansari, N. N., Bakasis, A., Kyrou, I., EFSTATHOPOULOS, E. P., Randeva, H. S., & Kassi, E. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063107 · Cited by 176
Lin, J., Huang, Y., Xu, B., Gu, X., Huang, J., Sun, J., Jia, L., Jiang, H., Huang, C., Wei, X., et al. (2025) · BMJ · doi:10.1136/bmj-2024-083735 · Cited by 147
Shen, Y., Cheng, L., Xu, M., Wang, W., Wan, Z., Xiong, H., Guo, W., Cai, M., & Xu, F. L. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155657 · Cited by 118
Metadata
- Authors
- Chehrehgosha, H., Sohrabi, M. R., Ismail-Beigi, F., Malek, M., Reza Babaei, M., Zamani, F., Ajdarkosh, H., Khoonsari, M., Fallah, A. E., & Khamseh, M. E.
- Affiliations
- Iran University of Medical Sciences (IR)
- Corresponding author
- Khamseh, Mohammad E.
- Venue
- Diabetes Therapy
- Published
- 2021-02-14
- Volume
- 12
- Issue
- 3
- Pages
- 843-861
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC7882235
- OpenAlex
- W3130225195
- Cited by
- 173
- References
- 86
- Citations by year
- 2026: 22 · 2025: 40 · 2024: 30 · 2023: 47 · 2022: 22 · 2021: 10
- FWCI
- 19.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Iran University of Medical Sciences
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- empagliflozin, pioglitazone, non-alcoholic fatty liver disease, type 2 diabetes, hepatic steatosis, liver fibrosis, controlled attenuation parameter, liver stiffness measurement, FibroScan, visceral fat, body composition, insulin resistance, SGLT2 inhibitors, thiazolidinediones, antidiabetic drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
